Nicholas Blagden

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/173900/publications.pdf

Version: 2024-02-01

49 papers	4,203 citations	201385 27 h-index	197535 49 g-index
52 all docs	52 docs citations	52 times ranked	4066 citing authors

#	Article	IF	Citations
1	Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Advanced Drug Delivery Reviews, 2007, 59, 617-630.	6.6	1,103
2	Polymorphism in Molecular Crystals:â€‰ Stabilization of a Metastable Form by Conformational Mimicry. Journal of the American Chemical Society, 1997, 119, 1767-1772.	6.6	321
3	Applying Hot-Stage Microscopy to Co-Crystal Screening: A Study of Nicotinamide with Seven Active Pharmaceutical Ingredients. Crystal Growth and Design, 2008, 8, 1697-1712.	1.4	293
4	Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling. Journal of Controlled Release, 2011, 149, 175-181.	4.8	209
5	Polymorph Selection:â€‰ Challenges for the Future?. Crystal Growth and Design, 2003, 3, 873-885.	1.4	206
6	Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors. International Journal of Pharmaceutics, 2009, 375, 107-113.	2.6	190
7	Crystal engineering â€“ nucleation, the key step. CrystEngComm, 2002, 4, 257-264.	1.3	189
8	Crystal chemistry and solvent effects in polymorphic systems Sulfathiazole. Journal of the Chemical Society, Faraday Transactions, 1998, 94, 1035-1044.	1.7	167
9	Crystal Polymorphism as a Probe for Molecular Self-Assembly during Nucleation from Solutions:â€‰ The Case of 2,6-Dihydroxybenzoic Acid. Crystal Growth and Design, 2001, 1, 59-65.	1.4	141
10	Current directions in co-crystal growth. New Journal of Chemistry, 2008, 32, 1659.	1.4	139
11	Disappearing polymorphs and the role of reaction by-products: the case of sulphathiazole. International Journal of Pharmaceutics, 1998, 172, 169-177.	2.6	103
12	Nucleation Control in Solution Mediated Polymorphic Phase Transformations:Â The Case of 2,6-Dihydroxybenzoic Acid. Journal of Physical Chemistry B, 2002, 106, 1954-1959.	1.2	102
13	Controlling the Formation of Benzoic Acid: Isonicotinamide Molecular Complexes. Crystal Growth and Design, 2009, 9, 47-56.	1.4	85
14	Pharmaceutical co-crystals â€“ are we there yet?. CrystEngComm, 2014, 16, 5753-5761.	1.3	85
15	A Whole Output Strategy for Polymorph Screening:â€‰ Combining Crystal Structure Prediction, Graph Set Analysis, and Targeted Crystallization Experiments in the Case of Diflunisal. Crystal Growth and Design, 2003, 3, 151-158.	1.4	76
16	Polymorphism in Benzamide. Angewandte Chemie - International Edition, 2005, 44, 7032-7035.	7.2	71
17	Artificial neural networks modelling the prednisolone nanoprecipitation in microfluidic reactors. European Journal of Pharmaceutical Sciences, 2009, 37, 514-522.	1.9	51
18	Solubility of Budesonide, Hydrocortisone, and Prednisolone in Ethanol + Water Mixtures at 298.2 K. Journal of Chemical & Engineering Data, 2010, 55, 578-582.	1.0	43

#	Article	IF	Citations
19	Woehler and Liebig Revisited:â€‰ A Small Molecule Reveals Its SecretsThe Crystal Structure of the Unstable Polymorph of Benzamide Solved after 173 Years. Crystal Growth and Design, 2005, 5, 2218-2224.	1.4	40
20	Spontaneous crystal growth of co-crystals: the contribution of particle size reduction and convection mixing of the co-formers. CrystEngComm, 2011, 13, 1141-1152.	1.3	39
21	Designing Hydrogen Bonds with Temperature-Dependent Proton Disorder:â€‰ The Effect of Crystal Environment. Crystal Growth and Design, 2007, 7, 531-534.	1.4	34
22	Tuning Proton Behavior in a Ternary Molecular Complex. Crystal Growth and Design, 2010, 10, 2770-2774.	1.4	34
23	Can crystal structure prediction be used as part of an integrated strategy for ensuring maximum diversity of isolated crystal forms? The case of 2-amino-4-nitrophenol. Physical Chemistry Chemical Physics, 2001, 3, 3819-3825.	1.3	33
24	Crystal engineering of polymorph appearance: the case of sulphathiazole. Powder Technology, 2001, 121, 46-52.	2.1	33
25	Creation of Ternary Multicomponent Crystals by Exploitation of Chargeâ€Transfer Interactions. Chemistry - A European Journal, 2013, 19, 10663-10671.	1.7	33
26	Stabilizing a solidâ€“solid interface with a molecular-scale adhesive. Nature, 1999, 402, 797-799.	13.7	31
27	Influence of Solvent on the Morphology and Subsequent Comminution of Ibuprofen Crystals by Air Jet Milling. Journal of Pharmaceutical Sciences, 2012, 101, 1108-1119.	1.6	30
28	Tuning Proton Disorder in 3,5-Dinitrobenzoic Acid Dimers: the Effect of Local Environment. Crystal Growth and Design, 2013, 13, 497-509.	1.4	30
29	Stoichiometric Control of Co-Crystal Formation by Solvent Free Continuous Co-Crystallization (SFCC). Crystal Growth and Design, 2015, 15, 5648-5651.	1.4	25
30	Solvent Influences on Metastable Polymorph Lifetimes: Real-Time Interconversions Using Energy Dispersive X-Ray Diffractometry**We dedicate this paper to Professor David Grant. Not only a talented scientist, he was a man who gave freely of his time and ideas to support and encourage others, including ourselves.. Journal of Pharmaceutical Sciences, 2007, 96, 1069-1078.	1.6	24
31	Development of a novel liquid crystal based cell traction force transducer system. Biosensors and Bioelectronics, 2013, 39, 14-20.	5.3	23
32	A Novel Batch Cooling Crystallizer for in Situ Monitoring of Solution Crystallization Using Energy Dispersive X-ray Diffraction. Crystal Growth and Design, 2003, 3, 197-201.	1.4	22
33	Serendipitous isolation of a disappearing conformational polymorph of succinic acid challenges computational polymorph prediction. CrystEngComm, 2018, 20, 3971-3977.	1.3	19
34	Growth of an Organic Co-Crystal upon a Component Subphase. Crystal Growth and Design, 2008, 8, 363-368.	1.4	18
35	Solubility of salbutamol and salbutamol sulphate in ethanol+water mixtures at 25Â°C. Journal of Molecular Liquids, 2012, 173, 62-65.	2.3	18
36	Application of Crystallization Inhibitors to Chiral Separations. 1. Design of Additives to Discriminate between the Racemic Compound and the Pure Enantiomer of Mandelic Acid. Crystal Growth and Design, 2007, 7, 218-224.	1.4	16

#	Article	IF	Citations
37	Rational Development of a Carrier-Free Dry Powder Inhalation Formulation for Respiratory Viral Infections via Quality by Design: A Drug-Drug Cocrystal of Favipiravir and Theophylline. Pharmaceutics, 2022, 14, 300.	2.0	16
38	First Comparative Study of the Three Polymorphs of Bis(isonicotinamide) Citric Acid Cocrystals and the Concomitant Salt 4-Carbamoylpyridinium Citrate Isonicotinamide. Crystal Growth and Design, 2018, 18, 4150-4159.	1.4	15
39	Ordered Aggregation of Benzamide Crystals Induced Using a â€œMotif Capperâ€•Additive. Crystal Growth and Design, 2005, 5, 467-471.	1.4	14
40	Rheological characterization and in-situ investigation of the time-dependent cholesteric based lyotropic liquid crystals. Materials Science and Engineering C, 2011, 31, 1389-1397.	3.8	12
41	Formation of a hybrid coordination-molecular complex. CrystEngComm, 2009, 11, 1793.	1.3	11
42	Chameleon Behavior of a New Salt of 3-(Aminocarbonyl) Pyridinium Malonate and Implications for Polymorphism on the Salt/Cocrystal Continuum. Crystal Growth and Design, 2022, 22, 1665-1679.	1.4	9
43	Impact of Mixed Solvent on Co-Crystal Solubility, Ternary Phase Diagram, and Crystallization Scale Up. Crystal Growth and Design, 2016, 16, 1817-1823.	1.4	8
44	First Steps for the Direct Purification of <scp>l</scp>-Leu-<scp>l</scp>-Leu Dipeptide through Co-Crystallization. Crystal Growth and Design, 2018, 18, 1062-1069.	1.4	5
45	Crystal Assembly:â€‰ The Application of High Affinity Ligands and Habit Modification. Crystal Growth and Design, 2003, 3, 167-173.	1.4	4
46	Evaluation of a Nanodispersion Formulation Prepared through Microfluidic Reactors for Pulmonary Delivery of Budesonide Using Nebulizers. Iranian Journal of Pharmaceutical Research, 2014, 13, 785-95.	0.3	4
47	The Impact of Trifluoroacetic Acid on Peptide Cocrystallization: Multicomponent Crystals of <scp>l</scp>-Leu-<scp>l</scp>-Leu Dipeptides. Crystal Growth and Design, 2018, 18, 4682-4690.	1.4	2
48	Crystal Growth. , 1999, , 127-153.		2
49	Crystal Growth Mechanisms. , 2004, , 364-370.		0